Alvotech (ALVO) Stock Price, Quote & News

Company Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosim...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Website: www.alvotech.com

Address:

9, Rue de Bitbourg, Luxembourg, Luxembourg

Zhezha Aug. 7 at 4:35 PM

$ALVO me, still talking to myself

1 · Reply

Zhezha Jul. 30 at 3:14 PM

$ALVO slow

0 · Reply

ZacksResearch Jul. 30 at 3:07 PM

$ALVO's Q2 earnings: Will the impressive surprise history continue? Despite a strong earnings surprise history, delivering an average surprise of 244.18%, ALVO's current setup might not support another beat. The Earnings ESP stands at 0.00%. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2638948/alvotech-gears-up-to-report-q2-earnings-heres-what-to-expect?cid=sm-stocktwits-2-2638948-body-4796&ADID=SYND_STOCKTWITS_TWEET_2_2638948_BODY_4796

0 · Reply

ZacksResearch Jul. 30 at 1:28 PM

$ALVO preps Q2 — is early U.S. momentum real or just hype? Investors watching closely for signs of traction from Simlandi and Selarsdi, along with pipeline updates that could shape sentiment. Full earnings preview here 👉 https://www.zacks.com/stock/news/2638948/alvotech-gears-up-to-report-q2-earnings-heres-what-to-expect?cid=sm-stocktwits-2-2638948-teaser-4718&ADID=SYND_STOCKTWITS_TWEET_2_2638948_TEASER_4718

0 · Reply

MGeronimo Jul. 22 at 7:29 PM

$ALVO IN AT 8.68 4x normal buy in

0 · Reply

JarvisFlow Jul. 18 at 6:01 PM

UBS has adjusted their stance on Alvotech ( $ALVO ), setting the rating to Buy with a target price of 16 → 14.

0 · Reply

RunnerSignals Jul. 17 at 4:13 AM

Testing the bounce $ERIC $VCIG $AA $ALVO $OSCR all flirting with support like its prom night

0 · Reply

Zhezha Jul. 15 at 7:36 PM

$ALVO this is so strange

0 · Reply

TravelingTraderNL Jul. 15 at 3:27 PM

$ALVO 400% daily average volume

0 · Reply

Thestocktraderhubzee Jun. 25 at 9:52 AM

WATCHLIST JUN 25 2025 $LAES WISeSat And Astrocast Join Forces To Expand Secure Satellite Communications and Reinforce European Space Autonomy With Access To Astrocast's Nanosatellite Network $FFAI Faraday X Confirms FX Super One Debut At Invite-Only Los Angeles Event Featuring FF Stakeholders, Investors, Influencers, And Test Drive Experiences $ECX ECARX Signs Lidar Partnership With Global Robotic Lawn Mower Developer, Expanding Beyond Automotive Into AI-Driven Robotics $ALVO Alvotech, Kashiv, And Advanz Pharma Report Top Line Results For Xolair Biosimilar AVT23 In Confirmatory Efficacy Study $PONY Pony.ai Says It Is Added To Nasdaq Golden Dragon China Index On June 23 As Sole Autonomous Driving Firm

0 · Reply

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

Jul 10, 2025, 4:40 AM EDT - 4 weeks ago

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

Jul 9, 2025, 4:30 AM EDT - 4 weeks ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

Jul 9, 2025, 4:30 AM EDT - 4 weeks ago

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee in Switzerland

Jul 3, 2025, 7:02 PM EDT - 5 weeks ago

Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers

Jul 1, 2025, 7:54 PM EDT - 5 weeks ago

Granting of Stock Options and Vesting of Restricted Share Units

Jul 1, 2025, 4:00 AM EDT - 5 weeks ago

Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)

Jun 26, 2025, 4:15 AM EDT - 6 weeks ago

Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility

Jun 25, 2025, 4:45 PM EDT - 6 weeks ago

Main Results of 2025 Annual and Extraordinary General Meeting

Jun 25, 2025, 4:00 AM EDT - 6 weeks ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 25, 2025, 4:00 AM EDT - 6 weeks ago

Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair® (omalizumab)

Jun 23, 2025, 4:00 AM EDT - 6 weeks ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 23, 2025, 4:00 AM EDT - 6 weeks ago

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

Jun 11, 2025, 4:20 PM EDT - 2 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 11, 2025, 4:18 PM EDT - 2 months ago

Alvotech's Private Placement Completed with Delivery of SDRs and Shares to Investors

Jun 6, 2025, 8:30 AM EDT - 2 months ago

Alvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami

Jun 6, 2025, 8:30 AM EDT - 2 months ago

Alvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami

Jun 5, 2025, 1:56 PM EDT - 2 months ago

Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug

MRK RDY

Jun 4, 2025, 10:29 PM EDT - 2 months ago

Alvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million

Jun 4, 2025, 11:32 AM EDT - 2 months ago

Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares

Jun 4, 2025, 7:45 AM EDT - 2 months ago

Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®

Jun 2, 2025, 9:15 AM EDT - 2 months ago

Alvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY

May 28, 2025, 6:15 AM EDT - 2 months ago

Alvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe

May 26, 2025, 2:06 PM EDT - 2 months ago

Alvotech Annual General Meeting to be held June 25, 2025

May 23, 2025, 12:11 PM EDT - 2 months ago

Transactions of Managers and Closely Associated Persons

May 19, 2025, 3:15 AM EDT - 2 months ago

Alvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm

May 19, 2025, 2:30 AM EDT - 2 months ago

Trading in Alvotech's Shares on Nasdaq Stockholm Commences Today

May 16, 2025, 1:52 PM EDT - 3 months ago

Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm

May 11, 2025, 1:08 AM EDT - 3 months ago

Alvotech (ALVO) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:30 AM EDT - 3 months ago

Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm

May 7, 2025, 4:45 PM EDT - 3 months ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 4:45 PM EDT - 3 months ago

Alvotech Reports Results for the First Quarter of 2025 and Provides Business Update

May 7, 2025, 5:00 AM EDT - 3 months ago

Potential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech's Product Revenues in 2025

May 2, 2025, 8:30 AM EDT - 3 months ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)

May 2, 2025, 8:30 AM EDT - 3 months ago

Alvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT

Apr 30, 2025, 4:39 PM EDT - 3 months ago

Alvotech: Potential Victim Of Pharma Tariff Threats (Rating Downgrade)

Mar 28, 2025, 5:01 PM EDT - 4 months ago

This Is a Test From GlobeNewswire

CMPS

Mar 27, 2025, 12:09 PM EDT - 4 months ago

Alvotech (ALVO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:30 AM EDT - 4 months ago

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Mar 26, 2025, 6:36 PM EDT - 4 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 6:34 PM EDT - 4 months ago

Alvotech Reports Record Results for 2024 and Provides Business Update

Mar 26, 2025, 4:30 AM EDT - 4 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 26, 2025, 4:30 AM EDT - 4 months ago

UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)

Mar 20, 2025, 3:00 AM EDT - 5 months ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 20, 2025, 3:00 AM EDT - 5 months ago

Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production

Mar 7, 2025, 9:00 AM EST - 5 months ago

Alvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida

Feb 24, 2025, 8:00 AM EST - 5 months ago

Alvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET

Feb 21, 2025, 6:44 AM EST - 6 months ago

Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara

JNJ TEVA

Feb 21, 2025, 6:00 AM EST - 6 months ago

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Feb 18, 2025, 11:30 AM EST - 6 months ago

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

TEVA

Zhezha Aug. 7 at 4:35 PM

$ALVO me, still talking to myself

1 · Reply

Zhezha Jul. 30 at 3:14 PM

$ALVO slow

0 · Reply

ZacksResearch Jul. 30 at 3:07 PM

0 · Reply

ZacksResearch Jul. 30 at 1:28 PM

0 · Reply

MGeronimo Jul. 22 at 7:29 PM

$ALVO IN AT 8.68 4x normal buy in

0 · Reply

JarvisFlow Jul. 18 at 6:01 PM

UBS has adjusted their stance on Alvotech ( $ALVO ), setting the rating to Buy with a target price of 16 → 14.

0 · Reply

RunnerSignals Jul. 17 at 4:13 AM

Testing the bounce $ERIC $VCIG $AA $ALVO $OSCR all flirting with support like its prom night

0 · Reply

Zhezha Jul. 15 at 7:36 PM

$ALVO this is so strange

0 · Reply

TravelingTraderNL Jul. 15 at 3:27 PM

$ALVO 400% daily average volume

0 · Reply

Thestocktraderhubzee Jun. 25 at 9:52 AM

0 · Reply

Arbor_Vitae Jun. 25 at 8:29 AM

$ALVO news

0 · Reply

Thestocktraderhubzee Jun. 23 at 9:34 AM

WATCHLIST JUN 23 2025 $HIVE HIVE Digital Technologies To Acquire 7.2 MW Toronto Data Center, Paving The Way For BUZZ HPC's Sovereign AI Infrastructure In Canada $BASE Piper Sandler Downgrades Couchbase to Neutral, Raises Price Target to $24.5 $VMAR Vision Marine Acquires Nautical Ventures, Forming North America's First High-Voltage Electric Boat Manufacturer With Full Retail And Service Infrastructure $SNY Sanofi's Sarclisa Set To Expand Front-Line Multiple Myeloma Use In EU Following Positive CHMP Opinion Backed By MRD And PFS Gains $ALVO European Medicines Agency Recommends Approval Of Alvotech's AVT06, A Proposed Biosimilar To Eylea, For Eye Disorders Across Europe

0 · Reply

ZacksResearch Jun. 5 at 3:01 PM

$RDY teams up with $ALVO to tackle $MRK's Keytruda! 💊 The new collaboration aims to co-develop a biosimilar to Keytruda, Merck's cancer treatment powerhouse, which saw a 6% sales growth YoY, enhancing RDY's biosimilar portfolio in emerging markets and ALVO's global pipeline expansion. 📈 See the full potential of this deal here 👉 https://www.zacks.com/commentary/2485940/rdy-alvo-ink-collaboration-deal-for-mercks-keytruda-biosimilar?cid=sm-stocktwits-2-2485940-body&ADID=SYND_STOCKTWITS_TWEET_2_2485940_BODY

0 · Reply

Wallst45 Jun. 5 at 11:38 AM

Alvotech $ALVO and Dr. Reddy's $RDY team up to co-develop a biosimilar to Keytruda, aiming to enhance global cancer treatment options. The collaboration will leverage both companies' biosimilar expertise Bad news for $MRK

0 · Reply

style345 Jun. 4 at 6:01 PM

$ALVO and I’m out for now. https://ca.finance.yahoo.com/news/alvotech-intends-carry-private-placement-153200243.html

0 · Reply

Dake0001 Jun. 4 at 3:00 PM

$ALVO https://mfn.se/a/xbrane-biopharma/xbrane-biopharma-completes-sale-of-xb003-and-parts-of-its-organization-to-alvotech

0 · Reply

Dake0001 Jun. 2 at 8:55 PM

$ALVO https://www.globenewswire.com/news-release/2025/03/20/3045966/0/en/Alvotech-Acquires-Xbrane-s-R-D-Operations-in-Sweden-and-Further-Affirms-its-Global-Leadership-Position-in-Biosimilars-Development-and-Production.html

1 · Reply

style345 May. 29 at 6:10 AM

$ALVO I am guessing I’ll be speaking to myself on this board for a some time. I bought based on fundamentals. I rarely see success in this industry though.

1 · Reply

style345 May. 27 at 2:11 PM

$ALVO I started a position here based on some fundamentals. Now to monitor to determine if this will be a solid long position like I hope.

0 · Reply

killasimba May. 27 at 1:45 PM

$ALVO why up?

0 · Reply

StockDudeIndy May. 9 at 3:31 PM

$TEVA I’m in on Teva, but $ALVO looks like a stock that could really take off. Strong earnings report too.

0 · Reply

Zhezha May. 8 at 11:58 AM

$ALVO go up more

0 · Reply

Market Cap	2.54B
Revenue (ttm)	489.68M
Net Income (ttm)	-231.86M
EPS (ttm)	N/A
PE Ratio	14.59
Forward PE	46.91
Profit Margin	-47.35%
Debt to Equity Ratio	-3.63

Volume	158,500
Avg Vol	268,076
Day's Range	N/A - N/A
Shares Out	301.48M
Stochastic %K	9%
Beta	0.11
Analysts	Sell
Price Target	$17.50